<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05032261</url>
  </required_header>
  <id_info>
    <org_study_id>LOCAL/2021/DC-01</org_study_id>
    <nct_id>NCT05032261</nct_id>
  </id_info>
  <brief_title>ICU Norepinephrine Load</brief_title>
  <acronym>ICU_NE_LOAD</acronym>
  <official_title>Norepinephrine Load and Relationship With Prognosis in Critically Patients With Circulatory Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Norepinephrine is recommended as first-line vasopressor in critically ill patients,&#xD;
      regardless of shock etiology. Its advantages over dopamine and/or epinephrine have been&#xD;
      demonstrated, especially by reducing tachycardia events. The current guidelines recommend a&#xD;
      mean arterial pressure of at least 65 mmHg that in the resuscitation from sepsis-induced&#xD;
      hypoperfusion. Some study reported that delay in initiation of vasopressor therapy was&#xD;
      associated with an increase mortality risk in patient with septic shock .The recent experts'&#xD;
      opinion suggest that &quot; vasopressors should be started early, before (complete) completion of&#xD;
      fluid ressuscitation &quot;.&#xD;
&#xD;
      In the event of refractory septic shock, high-dose vasopressors may be used. The precise&#xD;
      maximal dose of norepinephrine associated with mortality excess has been poorly studied. High&#xD;
      doses have been defined by a cutoff value ranging from 0.5 μg/kg/min to 2 μg/kg/min and&#xD;
      recently by 1 μg/kg/min for mortality at 90% and by 0,75 μg/kg/min for mortality at 60%.&#xD;
      Furthermore, an increasing vasopressor dosing intensity during the first 24 hours after shock&#xD;
      septic was associated with increased mortality depending of fluid administration. If a&#xD;
      threshold value of norepinephrine score can be obtained, it could indicate the association&#xD;
      with another vasopressor such as vasopressin or surrogates.&#xD;
&#xD;
      The primary aim of the present study aimed to confirm if a given norepinephrine dose is&#xD;
      associated with mortality. The secondary aims were the link between mortality and&#xD;
      norepinephrine duration, cumulative dose in order to build a score that predicts a futility&#xD;
      of increasing norepinephrine dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>Day 5</time_frame>
    <description>Mortality within 5 days of the date of ICU admission for circulatory shock according to norepinephrine intensity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intensity</measure>
    <time_frame>Day 5</time_frame>
    <description>Intensity mortality relationship according to norepinephrine duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time/Dose Ratio</measure>
    <time_frame>Day 5</time_frame>
    <description>ratio between time of use and cumulative dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Norepinephrine dose</measure>
    <time_frame>Day 5</time_frame>
    <description>score of increasing norepinephrine dose</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Circulatory Collapse and Shock</condition>
  <arm_group>
    <arm_group_label>Group 1: surviving Patients</arm_group_label>
    <description>Patients surviving within 5 days of the date of ICU admission for circulatory shock and receiving norepinephrine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Deceased patients</arm_group_label>
    <description>Patients deceased within 5 days of the date of ICU admission for circulatory shock and receiving norepinephrine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Circulatory shock with norepinephrine in ICU</intervention_name>
    <description>Circulatory shock with norepinephrine in ICU</description>
    <arm_group_label>Group 1: surviving Patients</arm_group_label>
    <arm_group_label>Group 2: Deceased patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with circulatory shock admitted in intensive care unit (ICU) and receiving&#xD;
        norepinephrine. We included all patients older than 18 years recorded between January 1,&#xD;
        2015 and December 31 to December, 31, 2019. Patients with circulatory shock without&#xD;
        norepinephrine were excluded.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  circulatory shock and admitted in ICU&#xD;
&#xD;
          -  with norepinephrine&#xD;
&#xD;
        Exclusion Criteria : Patient without norepinephrine or missing data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent Muller, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurent Muller, MD, PhD</last_name>
    <phone>+33.(0)4.66.68.33.31</phone>
    <email>laurent.muller@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Nîmes - Hôpital Universitaire Carémeau</name>
      <address>
        <city>Nîmes Cedex 09</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laurent MULLER, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Laurent Muller, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Norepinephrine load dose</keyword>
  <keyword>vasopressor dose intensity</keyword>
  <keyword>vasopressor exposure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norepinephrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

